Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

Esketamine and mental health represent a significant advancement in the treatment of depression, particularly for those who ...

Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname "Special K".

Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended for patients who have not responded to two other, conventional antidepressants which can ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who ...

6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO® has proven to be a ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...